6L9K
| H2-Ld a1a2 complexed with A5 peptide | Descriptor: | H2-Ld a1a2, SER-PRO-SER-TYR-ALA-TYR-HIS-GLN-PHE | Authors: | Wei, P.C, Yin, L. | Deposit date: | 2019-11-10 | Release date: | 2020-11-18 | Last modified: | 2023-11-22 | Method: | X-RAY DIFFRACTION (1.8 Å) | Cite: | Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer. Proc.Natl.Acad.Sci.USA, 118, 2021
|
|
6L9N
| H2-Ld complexed with A5 peptide | Descriptor: | MHC, SER-PRO-SER-TYR-ALA-TYR-HIS-GLN-PHE, b2m | Authors: | Wei, P.C, Yin, L. | Deposit date: | 2019-11-10 | Release date: | 2020-11-18 | Last modified: | 2023-11-22 | Method: | X-RAY DIFFRACTION (2.6 Å) | Cite: | Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer. Proc.Natl.Acad.Sci.USA, 118, 2021
|
|
6L9L
| 1D4 TCR recognition of H2-Ld a1a2 A5 Peptide Complexes | Descriptor: | H2-Ld a1a2, SER-PRO-SER-TYR-ALA-TYR-HIS-GLN-PHE, T Cell Receptor | Authors: | Wei, P.C, Yin, L. | Deposit date: | 2019-11-10 | Release date: | 2020-11-18 | Last modified: | 2023-11-22 | Method: | X-RAY DIFFRACTION (2.399 Å) | Cite: | Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer. Proc.Natl.Acad.Sci.USA, 118, 2021
|
|
6L9M
| H2-Ld complexed with AH1 peptide | Descriptor: | H2-Ld, SER-PRO-SER-TYR-VAL-TYR-HIS-GLN-PHE, b2m | Authors: | Wei, P.C, Yin, L. | Deposit date: | 2019-11-10 | Release date: | 2020-11-18 | Last modified: | 2023-11-22 | Method: | X-RAY DIFFRACTION (2.6 Å) | Cite: | Structures suggest an approach for converting weak self-peptide tumor antigens into superagonists for CD8 T cells in cancer. Proc.Natl.Acad.Sci.USA, 118, 2021
|
|